ArticleExperimental & molecular medicine2012
Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression.
Article in Experimental & molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- Exploring the Interactive Effect of Pectins fromACS omega · 2026Article
- Directing Neutrophil Fate via Sensory-Immune Interactions Accelerates Diabetic Bone Healing.Research (Washington, D.C.) · 2026Article
- RAGE ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression.Neuro-oncology · 2023Article
- Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.Oncology reports · 2023Article
- Galectin-3 promotes secretion of proteases that decrease epithelium integrity in human colon cancer cells.Cell death & disease · 2023Article
- The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.Advances in cancer research · 2023Review
- The Synthesis and Preclinical Investigation of Lactosamine-Based Radiopharmaceuticals for the Detection of Galectin-3-Expressing Melanoma Cells.Pharmaceutics · 2022Article
- Synthesis ofPharmaceutics · 2021Article
- Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.Journal for immunotherapy of cancer · 2021Article
- Review
- Enzymatically Extracted Apple Pectin Possesses Antioxidant and Antitumor Activity.Molecules (Basel, Switzerland) · 2021Article
- Genetic determinants of circulating galectin-3 levels in patients with coronary artery disease.Molecular genetics & genomic medicine · 2020Article
- Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior.Biomolecules · 2020Review
- An Insight into the Proteome of Uveal Melanoma-Derived Ectosomes Reveals the Presence of Potentially Useful Biomarkers.International journal of molecular sciences · 2019Article
- Post-translational modification of OCT4 in breast cancer tumorigenesis.Cell death and differentiation · 2018Article
- Galectin-3 and cancer stemness.Glycobiology · 2018Review
- Galectin-3 sensitized melanoma cell lines to vemurafenib (PLX4032) induced cell death through prevention of autophagy.Oncotarget · 2018Article
- Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44.PloS one · 2017Article
- Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.Oncotarget · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although mounting evidence indicates the involvement of galectin-3 in cancer progression and metastasis, the underlying molecular mechanisms remain largely unknown. In this study, we investigated the effect and possible mechanism of galectin-3 on the migration and invasion of B16F10, a metastatic melanoma cell line, in which galectin-3 and matrix metalloproteinase- 1 (MMP-1) were both found to be highly expressed. Knockdown of galectin-3 with specific siRNA reduced migration and invasion, which was associated with reduced expression of MMP-1. To further investigate the underlying mechanism, we examined the effect of galectin-3 knockdown on the activity of AP-1, a transcriptional factor regulating MMP-1 expression. We found that galectin-3 directly interacted with AP-1 and facilitated the binding of this complex to the MMP-1 promoter that drives MMP-1 transcription. Moreover, silencing of galectin-3 inhibited binding of fra-1 and c-Jun to promoter sites of MMP-1 gene. Consistent with these in vitro findings, our in vivo study demonstrated that galectin-3 shRNA treatment significantly reduced the total number of mouse lung metastatic nodules. Taken together, galectin- 3 facilitates cell migration and invasion in melanoma in vitro and can induce metastasis in vivo, in part through, regulating the transcription activity of AP-1 and thereby up-regulating MMP-1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.